Gliknik Adds Incyte President & CEO Paul A. Friedman to its Board of Directors

Gliknik Adds Incyte President & CEO Paul A. Friedman to its Board of Directors

PR Newswire

BALTIMORE, Feb. 25, 2013

BALTIMORE, Feb. 25, 2013 /PRNewswire/ --Gliknik Inc., a privately held
biopharmaceuticals company, today announced the appointment of Incyte
Corporation President and Chief Executive Officer Paul A. Friedman, M.D., to
its Board of Directors.Dr. Friedman, a seasoned pharmaceutical industry
executive with strong experience in management of R&D and corporate functions,
joins Gliknik's board as the company is continuing to advance its pipeline of
drug candidates targeting various cancers and immune disorders.

"It's an honor for us to welcome Paul to the Gliknik Board of Directors," said
Gliknik CEO David S. Block. "His deep experience in pharmaceutical research,
development, commercialization, and business development and his unwavering
commitment to excellence bring an important perspective to Gliknik as we seek
to advance and to partner our pipeline of novel therapies."

Dr. Friedman joined Incyte in 2001 as Chief Executive Officer and a Director.
A biopharmaceutical company focused on discovering, developing and
commercializing proprietary small molecule drugs for oncology and
inflammation, Incyte developed and commercialized Jakafi^® (ruxolitinib) under
Dr. Friedman and has a robust product pipeline. Previously, Dr. Friedman
served as President of R&D for the DuPont Merck Pharmaceutical Company,
President of DuPont Pharmaceuticals Research Laboratories, and Senior Vice
President at Merck Research Laboratories. Prior to his work at Merck and
DuPont, Dr. Friedman was an associate professor of medicine and pharmacology
at Harvard Medical School. Dr. Friedman is a diplomate of the American Board
of Internal Medicine and a member of the American Society of Clinical
Investigation. He received his A.B. in biology from Princeton University and
his M.D. from Harvard Medical School. Dr. Friedman is also a director of
Auxilium Pharmaceuticals, Inc.

"I welcome the opportunity to join the Gliknik Board of Directors and look
forward to contributing to its goal of advancing and partnering the company's
clinical immunomodulator and preclinical stradomer™ programs," said Dr.

About Gliknik Inc.
Founded in 2007, Gliknik is a biopharmaceuticals company creating new
therapies for patients with cancer and immune disorders. Gliknik expertise is
in modulation of the immune system to fight disease. In addition to the
stradomer^™ program for autoimmune diseases, Gliknik also has commercial
rights to two cancer immunomodulator drugs that are in multiple-dose clinical
trials in patients with advanced head and neck cancer and in patients with
advanced multiple myeloma. Learn more at

SOURCE Gliknik Inc.

Contact: Jamie Lacey-Moreira, PressComm PR, +1-410-299-3310,
Press spacebar to pause and continue. Press esc to stop.